#Sweden #Lund #Lilly #Camurus #FluidCrystal

Camurus and Eli Lilly Collaboration Expanded

In a significant development for the biopharmaceutical industry, Camurus, listed on NASDAQ Stockholm under the ticker symbol CAMX, recently announced an exciting update regarding its partnership with Eli Lilly and Company. Earlier today, on June 1, 2026, it was confirmed that Lilly has opted to extend their collaboration by including amylin receptor agonists in their existing agreement. This strategic move not only broadens Lilly's exclusive global rights to Camurus' innovative FluidCrystal® technology, but also introduces an additional class of compounds for the development of long-acting cardiometabolic medications.

The partnership originally established in June 2025 has now been fortified, allowing for up to four proprietary drug compounds under Lilly’s umbrella, specifically targeting three classes of receptor agonists: dual GLP-1 and GIP receptor agonists, triple agonists (GLP-1, GIP, and glucagon), and now, amylin receptor agonists.

Fredrik Tiberg, President and CEO of Camurus, expressed enthusiasm about this expansion, stating, "Lilly's decision to exercise the option validates our technology, broadens our partnership, and extends FluidCrystal into the expanding field of amylin therapeutics." Tiberg's remarks reflect a promising outlook on how this collaboration is evolving and the potential benefits it may lead to for patients in need of innovative treatment options.

Furthermore, the financial implications of this partnership are substantial. Under the current agreement, Camurus stands to gain up to $290 million in upfront developmental and regulatory milestone payments, along with an impressive $580 million in sales-based milestone payments. Additionally, tiered mid-single-digit royalties from product sales further enhance the potential financial returns from this collaboration. As a signal of commitment, the exercise of this option will trigger an initial payment of $5 million to Camurus within the ongoing partnership framework, adhering to the same royalty structure as existing compounds involved in the collaboration.

About FluidCrystal Technology

Camurus’ FluidCrystal technology represents a significant advancement in drug delivery systems. It is specifically crafted to dispense therapeutic drug levels across extended periods through a single injection, utilizing either a prefilled syringe or an autoinjector pen. Upon interacting with bodily fluids, this lipid solution morphs into a liquid crystalline gel, effectively encasing the active ingredient. As the gel gradually breaks down in tissue over time, it facilitates a slow, controlled release of the drug, making it an invaluable tool for long-term patient care.

The commercial viability and regulatory acceptance of the FluidCrystal technology are already established, as evidenced by existing market approvals and successful product sales in key markets including Europe, the United States, and Australia.

About Camurus

Camurus is an international, research-driven biopharmaceutical company dedicated to innovating long-acting medicines aimed at improving patient quality of life, particularly for those grappling with chronic and severe health conditions. Their development pipeline is robust and includes products aimed at treating various ailments, including dependence, pain, cancer, and endocrine disorders. With headquarters situated in Lund, Sweden, Camurus maintains operations across Europe, the US, and Australia, and is listed on the Nasdaq Stockholm under the ticker CAMX. For further insights into their innovative advancements, interested readers are encouraged to visit Camurus’ website.

This announcement is pivotal not only for Camurus and Lilly but also signifies advancements in therapeutic options available to patients, particularly in addressing cardiometabolic disorders. As both companies continue to collaborate and innovate, the potential for new, effective treatments will greatly benefit the healthcare landscape, moving forward.